Adequate B12 status is necessary for normal cellular function, but supraphysiological dosesbeyond correcting deficiencydo not demonstrably enhance metabolism in individuals with normal B12 levels
Retatrutide is an investigational triple receptor agonist developed by Eli Lilly, targeting GLP-1, GIP, and glucagon receptors simultaneously
This necessitates careful monitoring and likely medication adjustment
Anyone considering Epithalon should discuss their full medical history, current medications, and any cancer history with a physician first, since telomere-related interventions warrant careful individual review
Combining GLP-1 therapy with strength training and cardiovascular activity improves long-term outcomes
Dissimilar effects of curcumin on human granulosa cells: beyond its antioxidative role